UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Whole Disease Modeling to Inform Resource Allocation Decisions in Cancer: A Methodological Framework

Value in health, 2012-12, Vol.15 (8), p.1127-1136

2012

Volltextzugriff (PDF)

Using Whole Disease Modeling to Inform Resource Allocation Decisions: Economic Evaluation of a Clinical Guideline for Colorectal Cancer Using a Single Model

Value in health, 2013-06, Vol.16 (4), p.542-553

2013

Volltextzugriff (PDF)

The type and impact of Evidence Review Group (ERG) exploratory analyses in the NICE Single Technology Appraisal (STA) process

Value in health, 2017-06, Vol.20 (6), p.785-791

2017

Volltextzugriff (PDF)

Reviewing the Evidence to Inform the Population of Cost-Effectiveness Models within Health Technology Assessments

Value in health, 2013-07, Vol.16 (5), p.830-836

2013

Volltextzugriff (PDF)

Empirical Testing of Alternative Search Methods to Retrieve Utility Values for Health Economic Modelling

PharmacoEconomics, 2024-11, Vol.42 (11), p.1255-1266

2024

Volltextzugriff (PDF)

A stated preference binary choice experiment to explore NICE decision making

PharmacoEconomics, 2007-01, Vol.25 (8), p.685-693

2007

Volltextzugriff (PDF)

Distributional Cost-Effectiveness Analysis of Health Care Programmes - A Methodological Case Study of the UK Bowel Cancer Screening Programme

Health economics, 2015-06, Vol.24 (6), p.742-754

2015

Volltextzugriff (PDF)

Cost-Effectiveness of Disease-Modifying Therapies in the Management of Multiple Sclerosis for the Medicare Population

Value in health, 2009-07, Vol.12 (5), p.657-665

2009

Volltextzugriff (PDF)

Estimation of Transition Probabilities for State-Transition Models: A Review of NICE Appraisals

PharmacoEconomics, 2021-08, Vol.39 (8), p.869-878

2021

Volltextzugriff (PDF)

A Rapid-Response Economic Evaluation of the UK NHS Cancer Reform Strategy Breast Cancer Screening Program Extension via a Plausible Bounds Approach

Value in health, 2010-03, Vol.13 (2), p.215-221

2010

Volltextzugriff (PDF)

A Model-Based Economic Evaluation of Hypothetical Treatments for Amyotrophic Lateral Sclerosis in the UK: Implications for Pricing of New and Emerging Health Technologies

PharmacoEconomics, 2024-09, Vol.42 (9), p.1003-1016

2024

Volltextzugriff (PDF)

Improving Transparency in Decision Models: Current Issues and Potential Solutions

PharmacoEconomics, 2019-11, Vol.37 (11), p.1303-1304

2019

Volltextzugriff (PDF)

An Early Health Economic Analysis of the Potential Cost Effectiveness of an Adherence Intervention to Improve Outcomes for Patients with Cystic Fibrosis

PharmacoEconomics, 2017-06, Vol.35 (6), p.647-659

2017

Volltextzugriff (PDF)

Replicating Health Economic Models: Firm Foundations or a House of Cards?

PharmacoEconomics, 2017-11, Vol.35 (11), p.1113-1121

2017

Volltextzugriff (PDF)

A Systematic Review of Economic Models Across the Entire Schizophrenia Pathway

PharmacoEconomics, 2020-06, Vol.38 (6), p.537-555

2020

Volltextzugriff (PDF)

Response to ‘Comment on “Replicating Health Economic Models: Firm Foundations or a House of Cards?”’

PharmacoEconomics, 2017-11, Vol.35 (11), p.1189-1190

2017

Volltextzugriff (PDF)

Avoiding and Identifying Errors and Other Threats to the Credibility of Health Economic Models

PharmacoEconomics, 2014-10, Vol.32 (10), p.967-979

2014

Volltextzugriff (PDF)

Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

PharmacoEconomics, 2019-03, Vol.37 (3), p.333-343

2019

Volltextzugriff (PDF)

Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

PharmacoEconomics, 2017-07, Vol.35 (7), p.717-726

2017

Volltextzugriff (PDF)

Ibrutinib for Treating Waldenström’s Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

PharmacoEconomics, 2019-01, Vol.37 (1), p.7-18

2019

Volltextzugriff (PDF)

Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

PharmacoEconomics, 2016-03, Vol.34 (3), p.245-257

2016

Volltextzugriff (PDF)

Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

PharmacoEconomics, 2017-05, Vol.35 (5), p.537-547

2017

Volltextzugriff (PDF)

A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy

PharmacoEconomics, 2016-10, Vol.34 (10), p.1023-1038

2016

Volltextzugriff (PDF)

Simulation sample sizes for Monte Carlo partial EVPI calculations

Journal of health economics, 2010-05, Vol.29 (3), p.468-477

2010

Volltextzugriff (PDF)

Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

PharmacoEconomics, 2017, Vol.35 (1), p.97-109

2017

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Aktive Filter

ThemaBusiness & Economics

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(30)

Publikationsform

Artikel
(30)

Sprache

Englisch
(30)

Erscheinungsjahr

n.n

Thema

Economics
(30)
Health Care Sciences & Services
(30)
Health Policy & Services
(30)
Life Sciences & Biomedicine
(30)
Science & Technology
(30)
Social Sciences
(30)
Health Economics
(23)
Humans
(22)
Medicine
(21)
Medicine & Public Health
(21)
Pharmacoeconomics And Health Outcomes
(21)
Pharmacology & Pharmacy
(21)
Public Health
(21)
Cost-Benefit Analysis
(20)
Health Administration
(20)
Health Technology Assessment
(19)
Quality Of Life Research
(19)
Cost Analysis
(12)
Models, Economic
(12)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Pharmacoeconomics
(20)
Value In Health
(6)
Health Economics
(1)
Journal Of Health Economics
(1)
Pharmacoeconomics - Open
(1)
The European Journal Of Health Economics
(1)

1 weiteren anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Whole Disease Modeling to Inform Resource Allocation Decisions in Cancer: A Methodological Framework

Using Whole Disease Modeling to Inform Resource Allocation Decisions: Economic Evaluation of a Clinical Guideline for Colorectal Cancer Using a Single Model

The type and impact of Evidence Review Group (ERG) exploratory analyses in the NICE Single Technology Appraisal (STA) process

Reviewing the Evidence to Inform the Population of Cost-Effectiveness Models within Health Technology Assessments

Empirical Testing of Alternative Search Methods to Retrieve Utility Values for Health Economic Modelling

A stated preference binary choice experiment to explore NICE decision making

Distributional Cost-Effectiveness Analysis of Health Care Programmes - A Methodological Case Study of the UK Bowel Cancer Screening Programme

Cost-Effectiveness of Disease-Modifying Therapies in the Management of Multiple Sclerosis for the Medicare Population

Estimation of Transition Probabilities for State-Transition Models: A Review of NICE Appraisals

A Rapid-Response Economic Evaluation of the UK NHS Cancer Reform Strategy Breast Cancer Screening Program Extension via a Plausible Bounds Approach

A Model-Based Economic Evaluation of Hypothetical Treatments for Amyotrophic Lateral Sclerosis in the UK: Implications for Pricing of New and Emerging Health Technologies

Improving Transparency in Decision Models: Current Issues and Potential Solutions

An Early Health Economic Analysis of the Potential Cost Effectiveness of an Adherence Intervention to Improve Outcomes for Patients with Cystic Fibrosis

Replicating Health Economic Models: Firm Foundations or a House of Cards?

A Systematic Review of Economic Models Across the Entire Schizophrenia Pathway

Response to ‘Comment on “Replicating Health Economic Models: Firm Foundations or a House of Cards?”’

Avoiding and Identifying Errors and Other Threats to the Credibility of Health Economic Models

Ibrutinib for Treating Relapsed or Refractory Mantle Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Degarelix for Treating Advanced Hormone-Dependent Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Ibrutinib for Treating Waldenström’s Macroglobulinaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

A Model-Based Economic Evaluation of Biologic and Non-Biologic Options for the Treatment of Adults with Moderately-to-Severely Active Ulcerative Colitis after the Failure of Conventional Therapy

Simulation sample sizes for Monte Carlo partial EVPI calculations

Olaparib for Maintenance Treatment of BRCA 1 or 2 Mutated, Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer in People Whose Relapsed Disease has Responded to Platinum-Based Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Aktive Filter

Suchergebnisse filtern